Injectable poly-L-lactic acid: 3 Years of aesthetic experience

Dermatologic Surgery

Volumn 35, Issue SUPPL. 1, 2009, Pages 344-349

  Lowe, Nicholas J ^a,b,c   Maxwell, C Anne ^a,b   Lowe, Philippa ^a,b   Shah, Ardash ^a,b   Patnaik, Rickie ^a,b  

^a Cranley Clinic   (United Kingdom)

^b Clinical Research Specialists   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LIDOCAINE; POLYLACTIC ACID; WATER;

ADULT; AGED; ARTICLE; ESTHETICS; FACE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH; ORBIT; PAPULE; PRIORITY JOURNAL; QUESTIONNAIRE; SCAR; SKIN ATROPHY; SKIN BRUISING; SKIN NODULE; SURGICAL TECHNIQUE; SWELLING;

ADULT; AGED; CELLULOSE; COSMETIC TECHNIQUES; FACE; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; LACTIC ACID; MALE; MANNITOL; MIDDLE AGED; PROSTHESES AND IMPLANTS; RECONSTRUCTIVE SURGICAL PROCEDURES; RETREATMENT; RETROSPECTIVE STUDIES; SKIN AGING; TREATMENT OUTCOME;

EID: 59349088842     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2008.01061.x     Document Type: Article

References (15)

1. Werschler WP, Weinkle S. Longevity of effects of injectable products for soft-tissue augmentation. J Drugs Dermatol 2005 4 : 20 7.
2. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993 27 : 1135 48.
3. Barton SE, Engelhard P, Conant M. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS 2006 17 : 429 35.
4. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005 52 : 233 9.
5. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg 2006 118 : 46S 54S.
6. Engelhard P, Humble G, Mest D. Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther 2005 7 : 201 5.
7. Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 2005 18 : 273 8.
8. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006 118 : 55S 63S.
9. Sculptra® Product Information. sanofi-aventis; 2006. Available from : Accessed August 2007.
10. Vleggaar D. Poly-L-lactic acid: consultation on the injection techniques. J Eur Acad Dermatol Venereol 2006 20 (Suppl 1) : 17 21.
11. Lowe NJ. Dispelling the myth: appropriate use of poly-L-lactic acid and clinical considerations. J Eur Acad Dermatol Venereol 2006 20 (Suppl 1) : 2 6.
12. Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004 3 : 385 9.
13. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 2005 31 : 1616 25.
14. Bergeret-Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 2004 24 : 33 46.
15. Guaraldi G, Orlando G, De Fazio D, et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 2005 10 : 753 9.